1988
DOI: 10.1590/s0036-46651988000600008
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: SUMMARYA 2 7 yearjOl d mal e develope d seizure s afte r receivin g a singl e 2 0 mg/k g dos e of praziquante l fo r th e treatmen t o f a n intestina l Hymenolepi s nan a infection . O n further clinica l an d laboratoria l evaluations , h e wa s foun d t o suffe r fro m a n unti l then asymptomati c parenchyma l brai n cysticercosis . Praziquantel must b e use d wit h caution i n thos e areas where cysticercosi s represents a mayor publi c healt h problem . The occurrenc e o f unexpected seizure s in a n ind… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0

Year Published

1990
1990
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(7 citation statements)
references
References 8 publications
0
7
0
Order By: Relevance
“…The acceptable safety profile of niclosamide allowed our approach; safety concerns may preclude the use of praziquantel as an alternate drug in areas endemic for T. solium . 27 Unfortunately, we found that the efficacy of niclosamide was substantially lower than the 90% reported previously 28 ; among 38 humans with taeniasis who received niclosamide, 14 (36.8%; 95% CI, 21.8 to 54.0) were still infected 2 weeks after mass treatment in phase 1, as assessed by ELISA for coproantigen detection plus stool microscopy. The use of higher or repeated doses may increase efficacy but has not been evaluated for safety.…”
Section: Discussionmentioning
confidence: 58%
“…The acceptable safety profile of niclosamide allowed our approach; safety concerns may preclude the use of praziquantel as an alternate drug in areas endemic for T. solium . 27 Unfortunately, we found that the efficacy of niclosamide was substantially lower than the 90% reported previously 28 ; among 38 humans with taeniasis who received niclosamide, 14 (36.8%; 95% CI, 21.8 to 54.0) were still infected 2 weeks after mass treatment in phase 1, as assessed by ELISA for coproantigen detection plus stool microscopy. The use of higher or repeated doses may increase efficacy but has not been evaluated for safety.…”
Section: Discussionmentioning
confidence: 58%
“…However, reports of sudden onset of serious neurological signs and/or death after mass drug administration during which antihelminthic drugs are used at lower doses [praziquantel 40 mg/kg (single dose; frequency depending on endemicity level: maximum once a year) for schistosomiasis and 5 mg/kg/year (single dose) for taeniosis; albendazole as a 400 mg single dose for both soil-transmitted helminths and lymphatic filariasis (frequency depending on endemicity level: maximum every 6 months)] have also been noted. [32][33][34][35] Neurological side effects associated with imaging-confirmed exacerbation of NCC have been noted in a 12-year-old girl after a one-off intake of praziquantel at a dose as low as 5 mg/kg during mass treatment against human taeniosis for the control of cysticercosis 34,36 and in a young woman after self-medication for taeniosis with a single dose of 400 mg albendazole. 35 In 2010, 82 800 490 people received albendazole for lymphatic filariasis, 92 300 833 for soil-transmitted helminths and 27 811 183 people were given praziquantel for schistosomiasis.…”
Section: Asymptomatic Ncc and Mass Drug Administrationmentioning
confidence: 99%
“…104,106 However, when given by its own without steroids perifocal oedema around cysticerci in the brain or spinal cord may develop due to release of parasite antigen from viable cysticerci and may lead to neurological symptoms/signs in the treated individual (epileptic seizures, severe progressive headache; see above). So far, only case reports on the development of neurological symptoms/signs after administration of praziquantel have been published, [32][33][34] but a large community-based study on neurological side effects after mass drug administration of praziquantel is underway. Another approach may be a more focally directed treatment as clustering of human cysticercosis around tapeworm carriers has been shown to be present.…”
Section: Prevention Of Nccmentioning
confidence: 99%
“…These people are also at risk of developing symptomatic disease through mass drug administration for soil-transmitted helminths and schistosomiasis, among others [63][64][65][66]. Praziquantel and albendazole, two antihelminthic drugs (see 2.6.1.…”
Section: Prevalence Of Neurocysticercosis In Sub-saharan Africamentioning
confidence: 99%